Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA2001 Booster Study in Adults
NCT05364242Phase 3Completed
- Sponsor
- Valneva
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Viral Vector Vaccines, Whole Inactivated Vaccines
- Countries
- 2
01
Overview
Phase 3, open-label trial of VLA2001 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Valneva. Primary endpoints: Geometric Mean Titer fold-rise for neutralizing antibodies against SARS-CoV-2 at Day 15 and Frequency and severity of solicited Adverse Events at Day 7. Started May 2022; status: completed.
02
Drugs
VLA2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05364242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364242.